precisionmedicineonline4h
Tessellate Bio Partners With Australian Research Institutes to Study ALT-Driven Cancers
The collaboration will focus on researching the prevalence of ALT in cancer and its genetic drivers to develop new treatments.
precisionmedicineonline4h
Tesselate Bio Partners With Australian Research Institutes to Study ALT-Driven Cancers
The collaboration will focus on researching the prevalence of ALT in cancer and its genetic drivers to develop new treatments.
precisionmedicineonline6h
Prime Medicine Pipeline Prioritization, Licensing Deal With BMS to Fund Operations Into 2026
The firm is focusing on hematology, immunology, and oncology, liver, and lung conditions, while seeking partnerships beyond these core areas.
precisionmedicineonline7h
BioAI, Arbele Team up to Develop AI-Based Biomarker Screening Test
The companies will initially develop an AI-based test to select patients with CDH17-expressing gastrointestinal cancers for Arbele's Phase I drug trial.
precisionmedicineonline3d
FDA Grants Full Approval to Eli Lilly's Retevmo in RET-Mutant Medullary Thyroid Cancer
The agency converted a prior accelerated approval to a traditional approval based on results from the LIBRETTO-531 trial.
precisionmedicineonline3d
Case Study Suggests Role for Targeted Therapy in FGFR2 Fusion-Positive Pancreatic Cancer
Researchers are planning a clinical trial after four metastatic FGFR2 fusion-positive pancreatic cancer patients responded to ...
precisionmedicineonline3d
FDA Panel Finds Limited Immunotherapy Benefit in PD-L1-Negative Gastric, Esophageal Cancer
The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.
precisionmedicineonline3d
AI Tool Shows Promise for Predicting Genomic Alterations in Lung Cancer
Researchers hope DeepGEM can expedite targeted treatment for lung cancer patients who can't access standard genomic testing.
precisionmedicineonline3d
Memory Treatment Centers to Study Brain Volume Changes in Alzheimer's Patients on Anti-Amyloid Drugs
The Florida-based provider will work with AI software company AiraMed to analyze and measure patients' brain volume from MRIs.
precisionmedicineonline3d
858 Therapeutics Raises $50M in Series B Financing Round
NEW YORK – 858 Therapeutics on Thursday said it raised $50 million in a Series B financing round to advance its pipeline of small molecule therapeutics, including the poly (ADP) ribose glycohydrolase ...